The combination of BRAF and MEK inhibitors has demonstrated high efficacy in managing papillary craniopharyngiomas and other tumors with BRAF-V600E mutations, highlighting the potential of precision medicine. This evidence concerns the gene BRAF and Papillary Craniopharyngioma.